Dr. Hemanth Mishra

Biography

 Dr. Misra joined Prolong Pharmaceuticals as Vice President of Manufacturing and Facilities Operations. Hemant is a clinical drug development leader and has over 30 years of pharmaceutical and biopharmaceutical development, global clinical study management and corporate development experience. Prior to joining Prolong, Hemant managed the drug development, cGMP- manufacturing operation in US and abroad, CTM, quality system and multiple global clinical studies at XTL Biopharmaceuticals Inc. (a public biopharmaceutical firm). Hemant developed multiple antibodies and small molecules from R&D to various stages of clinical development and some of them (HepeX-B®; DOS program) were licensed to other firms at advance stage of clinical development. He served in the management team and directed Product Development with ActiveCyte Inc. MA, founded by The Boston Consulting Group, the leading strategy adviser to the global pharmaceutical industry. He managed a group of Ph.D. and MD scientists to oversee and ensure the scientific rigor of ActiveCyte’s proprietary licensing opportunity search services for innovative clinical drugs and technology for R&D. Prior to that Dr. Misra was Director of Clinical Drug Development and Corporate Development at Genzyme Transgenics (A public firm), a subsidiary of Genzyme Corporation, MA. He played a key role to licensing cancer vaccines (Stanford University) and developed the program with NCI and NIH under CRADA for multiple myeloma and B-cell lymphoma for Phase II. He supervised global clinical drug development for six MAbs (e.g. Humira, Orencia, Tysabri) and therapeutic proteins (Atryn, IFNs, hGH, cytokines, ILs, tPA, PDGF- developed by transgenic goats) with major global biopharma companies worldwide. He managed farm operations (transgenic goats) for different protein products and negotiated licensing opportunities. With a Ph.D. in Medicinal and Pharmaceutical Chemistry, Dr. Misra has published more than 50 publications and owns one Patent.

Research Interest

 Drug Development